Page 4«..3456..1020..»

Spectral Medical Announces the Appointment of Chris Seto to CEO

By Dr. Matthew Watson

Dr. Paul Walker will remain on the Board of Directors focusing on the seamless transition of management and on ensuring continuity of the Tigris Trial

Here is the original post:
Spectral Medical Announces the Appointment of Chris Seto to CEO

To Read More: Spectral Medical Announces the Appointment of Chris Seto to CEO
categoriaGlobal News Feed commentoComments Off on Spectral Medical Announces the Appointment of Chris Seto to CEO | dataMarch 8th, 2021
Read All

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

By Dr. Matthew Watson

PRESS RELEASE

Read this article:
Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

To Read More: Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity
categoriaGlobal News Feed commentoComments Off on Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity | dataMarch 8th, 2021
Read All

Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

By Dr. Matthew Watson

BASKING RIDGE, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to the Company’s CD34+ cell therapy product, CLBS12, for the treatment of Buerger’s disease – also known as thromboangiitis obliterans – a condition related to critical limb ischemia (“CLI”) with no approved treatments to date in the U.S. .

Continue reading here:
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

To Read More: Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease
categoriaGlobal News Feed commentoComments Off on Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease | dataMarch 8th, 2021
Read All

Gritstone Announces Promotions Within its Leadership Team

By Dr. Matthew Watson

EMERYVILLE, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced two promotions within its leadership team. Karin Jooss, Ph.D., previously the company’s executive vice president of research and chief scientific officer, has been appointed to the position of head of research and development. Erin Jones, M.S., who served as the company’s executive vice president of global regulatory affairs and quality, has been appointed to the position of chief operating officer (COO).

See more here:
Gritstone Announces Promotions Within its Leadership Team

To Read More: Gritstone Announces Promotions Within its Leadership Team
categoriaGlobal News Feed commentoComments Off on Gritstone Announces Promotions Within its Leadership Team | dataMarch 8th, 2021
Read All

Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference

By Dr. Matthew Watson

CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen, will present at the Oppenheimer 31st Annual Healthcare Conference being held March 16-18 2021.

Link:
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference

To Read More: Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference | dataMarch 8th, 2021
Read All

Silo Wellness Kicks Off Second Oregon Psychedelic Wellness Retreat

By Dr. Matthew Watson

TORONTO, March 08, 2021 (GLOBE NEWSWIRE) -- Silo Wellness Inc. (“Silo Wellness” or “the Company”) (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces, is pleased to announce that on Saturday, March 6, Silo launched its second ketamine-assisted psychedelic wellness retreat on the iconic McKenzie River in Oregon and third psychedelic retreat in 2021.

See more here:
Silo Wellness Kicks Off Second Oregon Psychedelic Wellness Retreat

To Read More: Silo Wellness Kicks Off Second Oregon Psychedelic Wellness Retreat
categoriaGlobal News Feed commentoComments Off on Silo Wellness Kicks Off Second Oregon Psychedelic Wellness Retreat | dataMarch 8th, 2021
Read All

TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors

By Dr. Matthew Watson

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Lisa Johnson-Pratt, M.D., Senior Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), to its Board of Directors.

Go here to see the original:
TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors

To Read More: TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors
categoriaGlobal News Feed commentoComments Off on TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors | dataMarch 8th, 2021
Read All

Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic…

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivered a presentation on its SARS-CoV-2 3CLpro inhibitor candidate, ALG-097111, at the 28th Conference on Retroviruses and Opportunistic Infections, being held virtually March 6 to March 10, 2021, during the meeting’s Science Spotlight sessions on Saturday, March 6. Aligos performed all research in collaboration with Belgian University KU Leuven, in particular its Centre for Drug Design and Discovery (CD3), and the Rega Institute for Medical Research.

Read the original post:
Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic...

To Read More: Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic…
categoriaGlobal News Feed commentoComments Off on Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic… | dataMarch 8th, 2021
Read All

Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board

By Dr. Matthew Watson

San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today the appointment of scientific innovators and cannabinoid experts, Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to its scientific advisory board.

Originally posted here:
Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board

To Read More: Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board
categoriaGlobal News Feed commentoComments Off on Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board | dataMarch 8th, 2021
Read All

Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

By Dr. Matthew Watson

AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the H.C. Wainwright Global Life Sciences Conference, a virtual event being held Tuesday, March 9th, and Wednesday, March 10th, 2021. Management is scheduled to present and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference.

See the article here:
Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

To Read More: Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
categoriaGlobal News Feed commentoComments Off on Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference | dataMarch 8th, 2021
Read All

Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021

By Dr. Matthew Watson

TORONTO, CHICAGO and MONTREAL, March 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, will be conducting 1x1 meetings with investors during the 33rd Annual Roth Conference being held virtually from March 15th – March 17th, 2021.

Link:
Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021

To Read More: Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021
categoriaGlobal News Feed commentoComments Off on Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021 | dataMarch 8th, 2021
Read All

Fierce Medtech Names Canary Medical a “Fierce 15” Company for 2020

By Dr. Matthew Watson

VANCOUVER, British Columbia and CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Canary Medical today announced that it has been named by Fierce Medtech as one of 2020’s Fierce 15, designating it as one of the most promising private companies in the industry.

View post:
Fierce Medtech Names Canary Medical a “Fierce 15” Company for 2020

To Read More: Fierce Medtech Names Canary Medical a “Fierce 15” Company for 2020
categoriaGlobal News Feed commentoComments Off on Fierce Medtech Names Canary Medical a “Fierce 15” Company for 2020 | dataMarch 8th, 2021
Read All

INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021

By Dr. Matthew Watson

LA JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that its management team is scheduled to participate in two upcoming virtual investor conferences in March 2021.

Read the rest here:
INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021

To Read More: INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
categoriaGlobal News Feed commentoComments Off on INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 | dataMarch 8th, 2021
Read All

XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

By Dr. Matthew Watson

? Compositions and Methods for Enhancing Anti-viral Therapies ?

Visit link:
XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

To Read More: XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection
categoriaGlobal News Feed commentoComments Off on XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection | dataMarch 8th, 2021
Read All

AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test

By Dr. Matthew Watson

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has successfully completed point-of-care clinical trials on its much awaited ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies to help understand COVID-19 immunity, validate vaccine’s effectiveness and estimate how long the vaccine will be effective in patients.

Continued here:
AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test

To Read More: AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test
categoriaGlobal News Feed commentoComments Off on AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test | dataMarch 8th, 2021
Read All

Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March

By Dr. Matthew Watson

CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), announced today that its management will be presenting and participating in panel discussions at the following industry conferences:

Original post:
Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March

To Read More: Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March
categoriaGlobal News Feed commentoComments Off on Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March | dataMarch 8th, 2021
Read All

AgraFlora Appoints Elise Coppens as New CEO and Director to Implement the Next Phase of its Corporate Strategy

By Dr. Matthew Watson

VANCOUVER, British Columbia, March 08, 2021 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce that Elise Coppens has been appointed as AgraFlora’s new Chief Executive Officer (“CEO”) and a member of the Company’s board of directors (“Director”) effective March 8, 2021, subject to the final acceptance of the Canadian Securities Exchange (the “CSE”). During her career in the Canadian cannabis industry, Ms. Coppens’ roles have included but are not limited to serving as President of Bloomera, Marketing Director for Aurora Cannabis and the Director of International Sales for Ample Organics.

View original post here:
AgraFlora Appoints Elise Coppens as New CEO and Director to Implement the Next Phase of its Corporate Strategy

To Read More: AgraFlora Appoints Elise Coppens as New CEO and Director to Implement the Next Phase of its Corporate Strategy
categoriaGlobal News Feed commentoComments Off on AgraFlora Appoints Elise Coppens as New CEO and Director to Implement the Next Phase of its Corporate Strategy | dataMarch 8th, 2021
Read All

AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study

By Dr. Matthew Watson

Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases

Read more here:
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study

To Read More: AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
categoriaGlobal News Feed commentoComments Off on AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study | dataMarch 8th, 2021
Read All

Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s…

By Dr. Matthew Watson

SAN CARLOS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced it will be delivering a presentation of data from a completed study of its therapeutic plasma fraction candidate, GRF6021, in subjects with Parkinson’s disease (PD) and cognitive impairment at the virtual 15th International Conference on Alzheimer’s and Parkinson’s Diseases. Presentation and discussion session details are included below.

View original post here:
Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s...

To Read More: Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s…
categoriaGlobal News Feed commentoComments Off on Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s… | dataMarch 8th, 2021
Read All

Global WholeHealth Partners Corp (OTC:GWHP) to Announce that Global is Now Offering the AstraZeneca Vaccines as Mentioned in 8K Filing on 03/02/21

By Dr. Matthew Watson

Global continues the fight against COVID-19 by now offering the vaccine

See the original post here:
Global WholeHealth Partners Corp (OTC:GWHP) to Announce that Global is Now Offering the AstraZeneca Vaccines as Mentioned in 8K Filing on 03/02/21

To Read More: Global WholeHealth Partners Corp (OTC:GWHP) to Announce that Global is Now Offering the AstraZeneca Vaccines as Mentioned in 8K Filing on 03/02/21
categoriaGlobal News Feed commentoComments Off on Global WholeHealth Partners Corp (OTC:GWHP) to Announce that Global is Now Offering the AstraZeneca Vaccines as Mentioned in 8K Filing on 03/02/21 | dataMarch 8th, 2021
Read All

Page 4«..3456..1020..»